rawlins_nice

NICE chairman joins biotech Board

pharmafile | May 17, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Intra-Cellular Therapies, NICE, Rawlins 

Biotech firm Intra-Cellular Therapies has appointed former NICE chairman Professor Sir Michael Rawlins to its Board of directors.

Rawlins was a leading figure in the field of drug safety, clinical effectiveness and cost effectiveness, having been chairman of the UK’s National Institute for Clinical Excellence from 1999 (at its inception) until March this year.

Recently Rawlins assumed the presidency of the UK’s Royal Society of Medicine, a centre for education and scholarship both in the UK and globally. Rawlins had a distinguished career as professor of clinical pharmacology and a general physician at the University of Newcastle upon Tyne.  

He is the recipient of numerous honours over the years, such as the Hutchinson Medal in 2003, the Galen Medal in 2010, and the Prince Mahidol Award for Medicine in 2012. He was appointed Knight Bachelor in 1999.

“We are excited to have Sir Michael Rawlins join our Board,” stated Sharon Mates, chairman and chief executive of Intra-Cellular Therapies.  “His expertise in the cost effectiveness of new pharmaceuticals and other issues in health economics will be invaluable to Intra-Cellular Therapies. I look forward to working closely with Michael as we transition our clinical programs through late-stage development and commercial approval.”

“I am delighted to join the ITI Board of directors. It comprises a group of individuals who have made significant contributions to the advancement of medical science, biotech entrepreneurship and the development of drugs serving unmet medical needs,” said Rawlins.

Related Content

Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy

Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as …

NICE recommends migraine treatment for NHS use

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …

GSK’s Jemperli recommended by NICE for endometrial cancer treatment

GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended …

Latest content